Eli Lilly, Scorpion

Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to $2.5 billion
Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments. The company will acquire Scorpion's experimental oral therapy,
JPM25: Eli Lilly strikes $2.5B Scorpion buyout in twist to breast cancer tale
Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics’ PI3Kα pipeline for up to $2.5 billion.
Eli Lilly acquires cancer program from Scorpion Therapeutics in $2.5B deal
Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it broadens its pipeline.
Lilly pads cancer drug pipeline with Scorpion deal
The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new company holding its employees and other assets.
Eli Lilly to buy cancer drug developer Scorpion Therapeutics for up to $2.5 billion
Eli Lilly said on Monday it would buy cancer therapy developer Scorpion Therapeutics for up to $2.5 billion in cash. Lilly will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors.
Eli Lilly To Buy Scorpion Therapeutics' Experimental Cancer Therapy For Up To $2.5 Bln In Cash
Eli Lilly and Company (LLY) on Monday said it has agreed to buy Scorpion Therapeutics' experimental cancer therapy PI3Ka inhibitor
Eli Lilly to buy cancer drugmaker Scorpion Therapeutics for up to $2.5 bn
Lilly will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors
Eli Lilly to buy cancer drug developer Scorpion Therapeutics for $2.5 bln
Eli Lilly said on Monday it would acquire cancer therapy developer Scorpion Therapeutics for $2.5 billion in cash.
Eli Lilly in advanced talks to buy US cancer biotech for up to $2.5bn
Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws
Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion. Eli Lilly (NYSE:LLY) is expected to pay around $1 billion upfront for the privately owned Scorpion,
Lilly to pay $2.5B for Boston biotech's lead cancer drug
Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...
TransMedics says claims made by Scorpion Capital ‘have no merit’
Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...
4,100-year-old Egyptian tomb belongs to royal courtier with unique life-saving skill
Swiss-French archaeologists have uncovered the 4,100-year-old tomb in Egypt that belonged to a royal physician with a very ...
China's Simcere Pharma grants AbbVie option to license its blood cancer drug candidate
Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...
Potential acquisition of Scorpion positive for Relay, says Barclays
Barclays says reports of Eli Lilly (LLY) reportedly being in talks to acquire Scorpion Therapeutics has a positive read-through to Relay ...
Rumored Spider-Man 4 Villains Would Bring Fan Favorite Characters To The MCU
Lisa Kudrow revealed during an interview on “The Drew Barrymore Show” (via People) that she recently discovered a note the ...
FailArmy on MSN1d
BMX Scorpion Bike Tangle and Crash Compilation
This video features a compilation of BMX crashes by various riders. One rider gets scorpioned when he trips over tree roots and another topples down the edge of the path.
Why TransMedics Group Stock Is Tanking Today
Shares of TransMedics Group ( TMDX -12.34%) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came after activist short seller Scorpion Capital released a scathing report about ...